Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data
| Autor: | Xiang-Yu Meng, Souraka Tapara Dramani Maman, Shuo Li, Sheng Li, Yong-Nong Xiao |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Article Subject Databases Factual lcsh:Medicine Antibodies Monoclonal Humanized Dexamethasone Disease-Free Survival General Biochemistry Genetics and Molecular Biology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Recurrence Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Progression-free survival Elotuzumab Lenalidomide Survival rate Survival analysis Aged Aged 80 and over General Immunology and Microbiology business.industry lcsh:R Hazard ratio General Medicine Middle Aged Carfilzomib Survival Rate Regimen chemistry 030220 oncology & carcinogenesis Female Multiple Myeloma business Oligopeptides Research Article 030215 immunology medicine.drug |
| Zdroj: | BioMed Research International, Vol 2018 (2018) BioMed Research International |
| ISSN: | 2314-6141 2314-6133 |
| Popis: | Background. Refractory and relapsed multiple myeloma (RRMM) remains a clinical challenge. We compared the progression-free survival (PFS) of RRMM patients treated with lenalidomide and low dose dexamethasone plus elotuzumab or carfilzomib (ELD vs. CLD), using reconstructed individual patient data (IPD) based on two published trials reports. Methods. We extracted data of study-level characteristics from original trial reports. We evaluated the comparability between the two treatment groups in terms of baseline status. Digitization of PFS Kaplan-Meier curves, reconstruction of IPD data, and subsequent survival analysis were performed. Distribution of progression and death events over time was visualized as histograms and corresponding kernel density lines, and Kaplan-Meier survival curves were plotted. Hazard ratio (HR) and corresponding 95% confidence interval (95% CI) were calculated. Results. Significant difference in race and disease stage distribution was found (P < 0.0001). Higher proportion of white patients and patients with advanced disease in the carfilzomib group was identified. Survival analysis revealed better PFS in the carfilzomib group (elotuzumab group vs. carfilzomib group: HR = 1.36, 95% CI = [1.11-1.67]). Conclusion. The CLD regimen may result in better PFS as compared with the ELD regimen in RRMM patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |